The Role of JDRF in Advancing Wearable Insulin Delivery Systems for Type 1 Diabetes

Living with type 1 diabetes (T1D) demands constant vigilance. Every meal, every exercise session, every moment of stress impacts blood glucose levels, requiring precise insulin adjustments. For decades, the standard of care involved multiple daily injections or reliance on traditional insulin pumps tethered to tubing. While effective, these methods impose a significant burden. Today, a new generation of wearable insulin delivery systems promises to simplify this complexity, and at the forefront of funding and accelerating their development is JDRF (formerly the Juvenile Diabetes Research Foundation). As the largest global nonprofit funder of T1D research, JDRF is channeling resources into partnerships, clinical trials, and policy advocacy to bring wearable systems from concept to clinic.

This article explores how JDRF is actively shaping the landscape of wearable insulin delivery, the technologies it supports, and what this means for the T1D community. We'll examine the specific mechanisms of JDRF's involvement, the challenges it addresses, and the promising future it is helping to build.

Why Wearable Insulin Delivery Matters

To understand JDRF's commitment, it's essential to recognize the shortcomings of existing insulin delivery methods. Traditional multiple daily injections (MDI) require users to calculate doses, draw insulin, and administer injections several times a day. This process is not only time-consuming but also prone to error, especially during sleep or stressful situations. Conventional insulin pumps offer more flexibility but involve a catheter inserted under the skin, connected to the pump via tubing. While an improvement, the tubing can snag, kink, or cause skin irritation, and the device must be worn continuously.

Wearable insulin delivery systems aim to eliminate these pain points. By miniaturizing pumps, integrating continuous glucose monitors (CGMs), and embedding intelligent algorithms, these next-generation devices offer:

  • Discreet and convenient wear: Patch-like devices adhere directly to the skin, with no external tubing.
  • Automated insulin adjustment: Closed-loop systems (often called artificial pancreas systems) automatically increase or decrease insulin delivery based on real-time CGM data.
  • Reduced cognitive load: Users spend less time calculating doses and managing devices.
  • Improved glucose outcomes: Automated adjustments help maintain time in range, reducing dangerous highs and lows.

For people with T1D, especially children and those with active lifestyles, these benefits translate into a better quality of life and long-term health. JDRF has recognized that accelerating the development of such systems is a pathway to its ultimate goal of curing T1D while dramatically improving life in the interim.

JDRF's Strategic Approach to Wearable System Development

JDRF's role is not simply to write checks. The organization employs a multifaceted strategy that spans research funding, industry collaboration, regulatory advocacy, and community engagement. Here are the key pillars of their approach.

Targeted Research Funding and Grant Programs

JDRF's research portfolio includes dozens of active grants focused on wearable insulin delivery. The organization prioritizes projects that address critical bottlenecks: improved sensor accuracy, algorithmic stability, miniaturization of pump components, and user interface design. For example, JDRF has funded early-stage development of microneedle patches that deliver insulin painlessly through the skin, as well as ultra-small pumps that can be worn for days without battery changes.

One notable initiative is the JDRF Artificial Pancreas Program, which has funneled millions of dollars into closed-loop technology since its inception. This program supports everything from preclinical algorithm testing to large-scale clinical trials. By funding many parallel approaches, JDRF reduces risk and ensures that promising ideas have a path to validation.

Forging Industry and Academic Partnerships

JDRF acts as a catalyst, bringing together biotech firms, device manufacturers, university labs, and healthcare systems. These collaborations are essential because wearable insulin systems require expertise in material science, electronics, software engineering, and clinical medicine. JDRF frequently convenes workshops and innovation challenges where researchers share data and align on technical standards.

For instance, JDRF has partnered with companies like Beta Bionics and Tandem Diabetes Care to accelerate their respective closed-loop systems. These partnerships often involve co-funding of clinical trials, regulatory navigation, and patient education resources. JDRF's seal of approval can also attract additional investment from venture capital and government agencies.

Facilitating Regulatory Pathways

Getting a wearable insulin delivery system to market requires navigating a complex regulatory landscape. In the United States, the Food and Drug Administration (FDA) must review safety and efficacy data for each component and the system as a whole. JDRF has a dedicated Therapeutic Affairs team that works with the FDA and international regulators to streamline approval processes.

This includes advocating for flexible clinical trial designs, such as adaptive trials that can be modified as data emerges. JDRF also pushes for post-market surveillance studies that allow devices to reach patients faster while still collecting long-term safety data. The organization's input has helped shape the FDA's guidance on interoperable pump and CGM systems, making it easier for different manufacturers' devices to work together.

“JDRF’s advocacy has been critical in moving the regulatory needle. They understand that patients need timely access to innovative devices, and they work tirelessly to balance speed with safety.” — Dr. Aaron Kowalski, CEO of JDRF

Patient-Centric Design and Education

Technological sophistication means little if patients cannot or will not use the device. JDRF funds user experience research to understand how people with T1D interact with wearable systems. This research informs design improvements such as easier insertion mechanisms, larger buttons for those with dexterity issues, and more intuitive smartphone apps.

JDRF also produces extensive educational content—webinars, guides, and online forums—to help patients and healthcare providers understand the benefits and limitations of new wearable systems. Their online technology resource library provides up-to-date comparisons of available and emerging devices.

Key Wearable Insulin Delivery Technologies Supported by JDRF

JDRF's portfolio spans a wide range of wearable concepts, from incremental improvements to radical innovations. Below are the major categories being advanced with JDRF backing.

Patch Pumps: Removing the Tubing

Patch pumps are small, disposable devices that adhere directly to the skin and deliver insulin through a short, pre-attached cannula. Unlike traditional pumps, they have no external tubing. JDRF has supported the development of several patch pump platforms, including the Omnipod system (by Insulet) and next-generation designs from startups.

Current research focuses on making patch pumps even smaller and longer-wearing. JDRF-funded projects are exploring biodegradable materials for the adhesive to reduce skin irritation, as well as on-board CGM integration so the patch can measure glucose levels at the same site as insulin delivery. This dual-function patch could simplify the device burden to a single wearable.

Closed-Loop Systems: The Artificial Pancreas

Closed-loop systems combine a CGM, control algorithm, and insulin pump to automatically manage blood sugar. JDRF has been a foundational supporter of closed-loop technology. The first hybrid closed-loop system (Medtronic’s 670G) received FDA approval in 2016, and JDRF’s early funding of the algorithms used in that device was crucial.

Today, advanced dual-hormone systems (delivering both insulin and glucagon) are in clinical trials with JDRF support. These systems aim to not only lower high blood sugar but also prevent hypoglycemia by delivering a small dose of glucagon when needed. Early results from JDRF-funded trials show significant improvements in time in range compared to standard therapy.

Smart Insulin Patches and Microneedles

Beyond traditional pumps, JDRF is investing in "smart" insulin patches that release insulin in response to glucose levels without any external electronics. These patches use microneedles coated with glucose-responsive polymers or enzyme-based sensors. When glucose levels rise, the patches release insulin automatically; when levels fall, release stops.

This technology, while still preclinical, has the potential to be truly wearable—applied like a band-aid and replaced every few days. JDRF has awarded substantial grants to teams at MIT, the University of California, and other institutions to refine these microneedle platforms. The goal is to create a painless, disposable, fully autonomous delivery system.

Implantable Systems for Long-Term Wear

Some JDRF-supported research is even more ambitious: fully implantable insulin delivery devices. These would be placed under the skin or within the abdominal cavity, with rechargeable batteries and remote drug reservoirs. While not strictly "wearable" in the external sense, they reduce the daily burden of device application. JDRF is funding early feasibility studies for such devices, focusing on biocompatibility and reliable power.

Overcoming Challenges: What JDRF's Support Addresses

Despite remarkable progress, the road to widespread adoption of wearable insulin systems is fraught with obstacles. JDRF's funding and advocacy are specifically designed to address these challenges.

  • Sensor accuracy and longevity: CGM sensors still need calibration and can drift over time. JDRF funds next-generation sensor chemistries and calibration algorithms to improve reliability.
  • Algorithm robustness: Closed-loop algorithms must handle unpredictable events like exercise, illness, and meals. JDRF sponsors large-scale real-world studies to train algorithms on diverse data.
  • User interface complexity: Many patients find current systems difficult to set up and operate. JDRF’s user design research leads to simpler onboarding and troubleshooting.
  • Cost and insurance coverage: Wearable systems can be expensive, and insurers often lag in coverage. JDRF’s advocacy efforts include working with payers to demonstrate long-term cost savings from improved outcomes.
  • Interoperability: Patients want the freedom to mix devices from different manufacturers. JDRF was instrumental in the development of the Interoperable CGM (iCGM) and Alternate Controller Enabled Infusion Pump (ACE-Pump) categories at the FDA, which allow different brands to work together.

The Impact: Real-World Outcomes from JDRF-Funded Research

The tangible results of JDRF’s investment are evident in clinical data and patient testimonials. A study published in Diabetes Care showed that children using a hybrid closed-loop system funded by JDRF experienced a 12% increase in time in range and a 40% reduction in hypoglycemia compared to sensor-augmented pump therapy. Adults using dual-hormone systems similarly reported improved glycemic stability and reduced anxiety about lows.

Beyond metrics, patients describe a transformation in daily life. “I used to wake up multiple times a night to check my blood sugar,” says Maria, a 34-year-old T1D patient who participated in a JDRF clinical trial for a wearable patch pump. “Now I trust the system, and I sleep through most nights. My A1c is the best it’s been in a decade.” Such stories underscore why JDRF continues to prioritize wearable systems: they yield measurable improvements in both health outcomes and quality of life.

Looking Ahead: JDRF's Vision for 2030

As part of its strategic plan, JDRF has articulated a vision for the next five to ten years. By 2030, the organization expects that most people with T1D will have access to an automated wearable insulin delivery system. Key milestones on the roadmap include:

  • Integration of ultra-long-term wear patches (7–14 days per application).
  • Full closed-loop systems that require zero user input (except occasional device replacement).
  • Affordable, globally accessible systems through economies of scale and health system partnerships.
  • Devices that also monitor ketones and other biomarkers to provide comprehensive diabetes management.

JDRF is already laying the groundwork by funding translational research that moves from bench to bedside more efficiently. The organization is also investing in data analytics platforms that aggregate real-world device data to accelerate iterative improvements.

How the Community Can Engage

JDRF’s success depends on a broad coalition of supporters. Individuals can get involved by:

  • Participating in clinical trials: JDRF maintains a searchable database of studies seeking volunteers at JDRF TrialNet.
  • Donating to wearable system research: Contributions can be designated for specific technology areas via JDRF’s donor portal.
  • Advocating for regulatory and insurance coverage: JDRF provides toolkits for patients to contact legislators and insurers.
  • Sharing experiences: User feedback helps developers refine device designs. JDRF hosts patient panels that feed directly into product development.

By supporting JDRF, the T1D community accelerates the move toward a world where diabetes management is nearly invisible.

Conclusion: A Foundation for Innovation

JDRF’s commitment to wearable insulin delivery systems is not a side project—it is a core pillar of its mission to improve lives and find a cure for type 1 diabetes. Through strategic funding, collaborative partnerships, regulatory savvy, and patient-centric design, JDRF has become an indispensable engine of innovation. The wearable systems that emerge from this pipeline will offer greater freedom, better outcomes, and reduced burden for millions of people worldwide.

As the organization continues to push boundaries, its work reminds us that while a cure remains the ultimate goal, the devices we have today can be made infinitely better. JDRF is making sure that promise becomes reality. For anyone touched by T1D, the future of insulin delivery has never looked more wearable.

For more information on JDRF’s funded projects and how to support wearable technology research, visit JDRF.org.